Introductory Chapter: Immunogenetics by Saghazadeh, Amene & Rezaei, Nima
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books









1.  Major histocompatibility complex (MHC): the master system for  
self-/nonself-recognition
It is a gene family found in many vertebrates. In humans, the “HLA” is inter-
changeably used with MHC. The MHC gene family is composed of three main 
subfamilies clustered near one another on chromosome 6. As shown in Figure 1, 
MHC class III genes space between MHC class I and class II genes. Glycoproteins 
encoded by MHC class I genes are present on the surface of all nucleated somatic 
cells, while the expression of MHC II glycoproteins is largely restricted to the spe-
cialized antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B 
cells. Both have extracellular domains that form the peptide-binding region. Those 
of MHC class I molecules govern the presentation of peptide (antigen) primarily 
derived from intracellular sources (endogenous) to CD8+ cytotoxic T lymphocytes 
(CTLs), while those of MHC class II molecules are particularly effective at presenta-
tion of peptide primarily originated from extracellular sources (exogenous) to CD4+ 
helper T (TH) cells. In the following, the specific mechanisms of action appear:
2. MHC class I
T-cell receptor (TCR) on the surface of CTLs interacts with peptide-MHC class 
I complex. It has the ability to discriminate self from foreign. CTLs are stimulated 
upon TCR recognition of foreign peptides. Stimulated CTLs promote T-cell prolif-
eration and lysis in peptide-pulsed target cells. Also MHC class I molecules interact 
with NK cell receptors, e.g., killer-immunoglobulin-like receptors (KIRs), thereby 
controlling effector functions of NK cells that can damage self-components, for 
example, cell cytotoxicity and excessive inflammation [1]. In this manner, MHC I 
molecules induce self-tolerance via a NK cell-dependent mechanism as well.
3. Class I MHC restriction of CTLs
Because both self and foreign peptides can bind to class I MHC molecules, so a 
question to ask is what would happen to class I MHC molecules loaded with self-
peptide. The answer lies within the process by which T lymphocytes are selected in the 
thymus. Thereby, CTLs can enter circulation if their surface TCR is reactive to self-
class I MHC molecules loaded with foreign, not self, peptides. This reaction is known 
as class I MHC restriction of CTLs, because it occurs only in the presence of self-class 
I MHC molecules (for review see [2]). As if, class I MHC molecules act as parent to 
CTLS. Two possibilities arise [3]. First, self-class I MHC compatibility is necessary for 
sensitizing of the foreign peptide and thereby for binding and lysis of the target cell 
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by CTLs. In this case, there might be specific MHC gene products and the interactions 
between them that function to distinguish self from foreign. Second, self-components 
undergo changes in composition on encountering foreign antigen, so that their recog-
nition is not possible unless a compatible class I MHC system is available.
4. MHC class II
4.1 Macrophages
Extracellular peptides or pathogens are engulfed by phagocytosis into macro-
phages and assembled into a vesicle, called phagosome. Lysosomes combine with 
the phagosome to digest substances in order to extract their antigens. MHC class 
II molecules orient antigens to the outer surface of cell membrane, where TH cells 
stand ready to bind and assist with recognition of antigens. Recognition of a foreign 
antigen by TH cells would force more macrophages to phagocyte pathogens.
Figure 1. 




Immunoglobulins are attached to the surface of B cells. Binding of a foreign 
antigen to these immunoglobulins induces the engulfment of that particular antigen 
by B cells. B cells prepare ingested antigen for presentation by MHC class II mol-
ecules. Peptide-MHC II complex would engage TH cells that promote proliferation 
of antibody-producing plasma cells. Antibodies produced by plasma cells enter the 
circulation and form complex with matching antigens. Matching antigen-antibody 
complexes are susceptible to cleavage.
In this manner, MHC class I and class II molecules are very important in the 
initiation of cell-mediated and antibody-mediated immune responses. As a result, 
they have always been in the center of attention of immunogeneticists.
5. The genetic architecture of human MHC
Figure 1 shows three main MHC classes of genes. Occupying about 0.1% of the 
human genome [4], the MHC ranks as the most gene-dense region in the human 
genome. Two hundred and twenty-four MHC loci have been so far isolated from 
humans, among which 20–30% [5] are associated with a known or putative func-
tion in innate and adaptive immune responses [4], while the rest act as mediators of 
growth, development, mating, reproduction, odor, and olfaction [6]. This would 
imply that MHC is working on contextually different aspects of the evolution. As 
in mammalian genome, some MHC genes related to adaptive immune system are 
present in invertebrate genomes. This would tell us that the origin of the adaptive 
immune system dates back to at least 400 million years ago [7].
6. Evolution and selection of MHC polymorphisms
The MHC class I and class II genes continue as the most polymorphic genes in 
mammals. However, there are specific loci that exhibit a higher level of polymor-
phism compared with other loci studied in the same population. Mounting evidence 
supports that selective MHC polymorphisms might play a role in evolution, so 
that they will be maintained within one species or even command one species to 
be transformed into another [8]. Different hypotheses exist regarding profitable 
variations that are provided by MHC polymorphisms making them favorable to 
be accumulated by natural selection. For example, in the context of immunity, the 
overdominance hypothesis states that individuals being heterozygous for those 
certain MHC polymorphisms, the so-called extraordinary polymorphisms, will 
have an advantage over the homozygous individuals that the MHC function is 
more powerful in terms of types of peptides that they can bind to and recognition 
of more peptide types, in turn, would mean protection against a broader range of 
pathogens. This is known as heterozygous advantage or overdominance selection. 
For more information regarding other hypotheses, please see [2, 9–12].
7. Challenges in mapping MHC genes
MHC loci are difficult to map due to a number of reasons including:




2. There is strong linkage disequilibrium between different loci that can influence 
the accuracy of analysis of the immunogenetic data.
3. There are nonadditive effects within the MHC loci and also epistatic interac-
tions between the MHC and other genes that are able to affect total genomic 
variance [4].
As detailed in [5], different approaches have been developed for sequencing the 
MHC and discovery of potential copy-number variation (CNV) and of SNP regions. 
Sanger sequencing combined with next-generation DNA sequencing technologies 
can be used to detect SNPs, describe their characteristics, and obtain information 
for haplotype phasing.
Serological techniques and solid-phase immunoassays offer HLA typing 
with an appropriate resolution [13]. However, it is noteworthy to mention that 
despite about one century of effort, HLA (class I and II) typing—which is used to 
match donor and recipient for transplantation of the stem cells, cord blood, and 
 kidney—might be challenging for bioinformaticians in some instances. Therefore, 
external proficiency testing (EPT) is performed to resolve ambiguities in HLA 
typing. According to a report of the Ad-Hoc Committee of the American Society for 
Histocompatibility and Immunogenetics, there is no need to resolve all ambiguous 
results [14]. The committee recommends that if there is more than one possible 
HLA genotype at the time of clinical decision-making, then we only need to refer 
to the criteria of EPT, which is attached to a list of common and well-documented 
(CWD) HLA alleles. For each HLA locus, e.g., HLA-A, HLA-B, HLA-C, HLA-DRB1, 
HLA-DQB1, HLA-DRB3/4/5, HLA-DQA1, and HLA-DPB1, CWD alleles consist of 
about 27–47% of the total alleles.
8. The international ImMunoGeneTics information system
For almost 30 years, the international ImMunoGeneTics (IMGT) information 
system has been made available free on http://imgt.cines.fr. IMGT is composed of 
immunogenetic information on sequences, nucleotides, genes and their polymor-
phisms, and proteins of the immune system including immunoglobulins or antibod-
ies, TCR, and MHC. It can be useful for diagnostic, therapeutic, and engineering 
purposes and also research in the different fields of medicine, in particular, autoim-
mune diseases, infectious diseases, acquired immunodeficiency syndrome (AIDS), 
and blood cancers. In this manner, IMGT helps operationalize the continuum 
between specialist and generalist databases.
9. Immunogenetics and inherited risk of multifactorial diseases
9.1 HLA loci
Genetic studies have provided evidence for association of loci on HLA and:
1. Autoimmune and inflammatory diseases: acute anterior uveitis, alopecia areata, 
asthma, atopic dermatitis, eczema, rheumatoid arthritis, Behçet’s disease, celiac 
disease, collagenous colitis, granulomatosis with polyangiitis (Wegener granu-
lomatosis), generalized vitiligo, IgA nephropathy, primary biliary cirrhosis, 
psoriasis, ankylosing spondylitis, systemic lupus erythematosus, vasculitis, type 1 
diabetes, Crohn’s disease, ulcerative colitis, dermatomyositis, and Graves’ disease
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2. Infections: human immunodeficiency virus (HIV) set-point viral load (spVL), 
HIV-1 control, acquired immunodeficiency syndrome (AIDS) progression, 
chronic hepatitis B infection and viral clearance, hepatitis B, hepatitis B and 
C virus-related hepatocellular carcinoma, hepatitis B-related liver cirrhosis, 
chronic hepatitis C infection, human papillomavirus (HPV) seropositivity, 
dengue shock syndrome, leprosy, M. tuberculosis infection, malaria, resistance 
to enteric fever, and visceral leishmaniasis
3. Gastrointestinal diseases: Barrett’s esophagus
4. Neurological disorders: Parkinson’s disease, narcolepsy, juvenile myoclonic 
epilepsy, spinocerebellar ataxia, myasthenia gravis, and multiple sclerosis
5. Psychiatric disorders: schizophrenia and autism
6. Joint diseases: knee osteoarthritis
7. Cancers of the nasopharynx, cervix, colorectum, lung, blood cells, and bone 
marrow (lymphoid cancers)
8. Adverse drug reactions: Stevens-Johnson syndrome/toxic epidermal necrolysis 
(carbamazepine), agranulocytosis (clozapine), pancreatitis (thiopurine), and 
liver injury (terbinafine, fenofibrate, ticlopidine, and pazopanib)
9. Response to vaccines: hepatitis B
10. Male infertility due to nonobstructive azoospermia
9.2 Non-HLA loci
Generally, loci on non-HLA genes are involved in genetic predisposition to a 
variety of autoimmune and inflammatory disorders, among which the most associ-
ated have been identified in three genes: cytotoxic T-lymphocyte-associated antigen 
4 (CTLA4), protein tyrosine phosphatase (PTPN22), and tumor necrosis factor-α 
(TNF). In particular, it is noticeable that patients who receive hematopoietic stem 
cell transplantation (SCT) from matched sibling donor might develop acute graft-
versus-host disease (GVHD). This reflects that non-HLA components have a part in 
making the immunogenetic profile that needs special attention in patients sched-
uled to undergo stem cell transplantation.
10. Immunogenetics and the spectrum of immune disorders
By engaging pattern recognition receptors (PRRs)—including Toll-like receptors 
(TLRs) and nucleotide-binding oligomerization domain-like receptors (NLRs)—and 
signal-transducing molecules, e.g., interleukin-1 receptor-associated kinase 4 (IRAK4), 
the innate immune system forms the center of recognition of molecular patterns and 
therefore the first line of defense against foreign antigens. Abnormally low activity of 
this system causes underdetection of foreign agents that makes individuals susceptible 
to being infected, while the unwanted action of this system is being reactive to self-com-
ponents, which is seen in autoimmune situations. In this manner, if anything hinders 
the proper functioning of the immune system, for example, genetic factors, then it is 
most likely that the body is prone to autoimmune and infectious diseases.
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Immunogenetics aims to cover HLA and non-HLA effects for all the aforemen-
tioned categories with emphasis on autoimmune disorders and infections, two ends 
of the spectrum of immune disorders.
11. Autoimmune diseases
11.1 Psoriasis
Psoriasis was initially known as a disease of abnormal keratinocyte prolifera-
tion presented with chronic plaque in the majority of instances that can predispose 
patients to cardiovascular, psychiatric, and joint complications. It is already consid-
ered an immune-mediated skin disease where both innate and adaptive immunities 
play a role in initiating psoriatic lesions. Of note, Th1 pathway is overstimulated; 
there are high levels of Th1 cytokines and chemokines including IL-2, IL-12, and 
IFN-γ in psoriatic plaques. T cells, natural killer cells, natural killer T cells, and, to a 
lesser extent, neutrophils contribute to cutaneous inflammation in psoriasis as well. 
More interestingly, dendritic cells through antigen presentation to T cells can lead to 
plaque formation.
Consistent with its different clinical facets, there is a catalog consisting more 
than 60 loci identified as risk genes for psoriasis. In particular, the risk allele at 
MHC class I gene is present in about half of patients with psoriasis. Generally, HLA 
and non-HLA genetic loci associated with psoriasis are important mediators of 
antigen presentation, Th17/IL-23 axis, T-cell function, antiviral immunity, mac-
rophage activation, and nuclear factor-κB (NF-κB)-dependent signaling. A simple 
mechanism for these genetic risk alleles in pathogenesis of psoriasis is likely to be 
mediated through reducing the threshold for activation of the innate immunity.
11.2 Rheumatoid arthritis (RA)
RA is a chronic inflammatory disease of synovial joints characterized by syno-
vial hyperplasia, production of autoantibodies such as rheumatoid factor (RF) 
and anti-citrullinated protein antibody (ACPA), bone deformity, and systemic 
manifestations. Collectively, RA is associated with unfavorable long-term progno-
sis. Different cells such as macrophages, monocytes, fibroblasts, and T cells act to 
make an orchestra of cytokines, e.g., IL-1, IL-6, and TNF-α, which are central to the 
abnormal signaling pathways underlying this inflammatory arthritis.
RA has a long-recognized association with alleles at MHC class II gene that 
contain a common amino acid sequence in the HLA-DRB1 region, e.g., HLA-
DRB1*0404 and DRB1*0401. In addition, there are non-HLA genetic loci associated 
with RA in ACPA-positive patients. As reviewed in [15], RA-associated genes are 
known to play a role in the nuclear factor-κB (NF-κB)-dependent signaling, TCR 
signaling, and JAK-STAT signaling.
11.3 Autoimmune thyroid diseases (AITDs)
As for other autoimmune disorders, AITDs such as Graves’s disease and 
Hashimoto’s thyroiditis are of T-cell-mediated autoimmune disorders mainly 
characterized by production of autoantibodies against and T-cell infiltration in the 
thyroid gland. Thereby, the immune system cannot correctly maintain a constant 
battle causing the gland to malfunction, which can be manifested as hyper- or 
hypothyroidism. Generally, AITDs are of special importance in practice because of 
their comorbidities with other autoimmune diseases.
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Among risk alleles for AITDs are genetic variants associated with thyroid 
function. However, a variety of AITDs-related genetic loci occur within immune-
modulating and HLA genes, which are known to contribute to peripheral tolerance, 
T-lymphocyte activation, and antigen presentation. In this manner, a mechanism 
of immunogenetic susceptibility to AITDs is maintained through interference with 
central and peripheral tolerance, APCs, and subsequent activation of T cells.
11.4 Primary biliary cirrhosis (PBC)
It is a disease of small intrahepatic bile ducts regarded as an autoimmune liver 
disease with the presence of the antimitochondrial antibody (AMA) in all except a 
minority of patients (up to 10%). Supporting this is that the infiltration of auto-
reactive CD4+ T cells and CD8+ T cell specific to AMA has increased manifold in 
the liver of patients with PBS. T cells along with other immune cells such as B cells, 
macrophages, eosinophils, and natural killer cells take part in the composition of 
the portal inflammation. Eventually, such a chronic inflammation would progress to 
the loss of biliary epithelial cells.
Genetic studies have detected HLA variants conferring susceptibility to 
PBC. However, there were HLA variants that seemed protective against PBC. Non-
HLA loci associated with PBC mainly involve genes associated with T cells. In 
particular, they contribute to IL-12-JAK-STAT4, CD80/CD86, and IL7R-α/CD127 
signaling pathways, which are known to play a role in Th1 T-cell polarization, TCR 
signaling, and T-cell homeostasis, respectively. Other PBC-associated non-HLA loci 
are related to B-cell function, TNF signaling, and NF-κB signaling.
11.5 Type 1 diabetes mellitus (T1DM)
T1DM is a T-cell-mediated autoimmune disorder characterized by the presence 
of autoantibodies against islet cells. Increasing incidence of T1DM and its potential 
microvascular and macrovascular complications have shed light on the need for 
identifying more effective prevention strategies and new treatment targets. To this 
end, it is essential to enhance our understanding of the pathogenesis of T1DM.
It is a polygenic disorder where the HLA class II genes account for almost half of 
genetic susceptibility for T1DM. Interestingly, there are loci of these genes that have 
also been associated with protection from T1DM. Of the so-far-identified non-HLA 
genes are a variable number of tandem mini-satellite repeats (VNTR) and CTLA-4.
11.6 Systemic lupus erythematosus (SLE)
It is a chronic autoimmune disease affecting multiple organ systems includ-
ing the skin, heart, blood, muscle and joints, kidneys, and lungs. As if, SLE is 
the winner of all fights with the immune system that is not possible unless the 
immune tolerance against self-components is broken. Activation of innate immune 
responses and of inflammatory processes along with production of type I interfer-
ons and autoantibodies favors pathogenesis of SLE, while mechanisms of clearance 
of immune complexes such as apoptosis, neutrophil extracellular traps (NET), and 
nucleic acid sensing are defective. In particular, evidence indicates the multifaceted 
role of neutrophils in SLE. Lupus neutrophils undergo epigenetic changes causing 
them to produce higher levels of cytokines that would induce T- and B-cell abnor-
malities. Also, neutrophils directly contribute to the formation of NET, which is 
increased in SLE, while clearance of NET materials is impaired in SLE.
As expected, such a complex situation involves contribution by both HLA 
and non-HLA genes. Several HLA genes including HLA-DRB1, HLA-DQB2, 
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HLA-DQA2, and HLA-DR3 have been associated with susceptibility to SLE and 
with the autoantibody profile (anti-dsDNA, anti-Ro, and anti-La) in patients 
with SLE. Genes encoding interferon regulatory factors (IRFs), STAT4, IFIH1, 
and osteopontin (OPN) contribute to polygenic high IFN signatures, while 
TREX1, STING, SAMHD1, and TRAP are known to give rise to monogenic high 
IFN signatures in SLE. Monogenic SLE results from mutation(s) in genes related 
to classical complement pathway, apoptosis, and antinucleosome antibody 
production. SLE-associated genes that occur in regulatory regions (e.g., exons, 
splice sites, introns, and intergenic sites) are TNFAIP3, TNIP1, BLK, ETS1, 
PRDM1, and IKZF1. Finally, there are SNPs located within the coding region of 
genes PTPN22 and immunoglobulin-like transcript 3 receptor (ILT3) that have 
been linked with SLE.
11.7 Systemic sclerosis (SSc)
SSc is considered a complex multisystem disease characterized by a heteroge-
neous spectrum of clinical manifestations ranging from limited to diffuse cutane-
ous SSc. Both innate and adaptive immune systems, fibroblasts, and small vessels 
show abnormal function in SSc.
There is a long list of HLA genes conferring susceptibility to clinical and auto-
antibody subgroups of SSc. Also, some HLA genes appear to be protective of SSc. 
Non-HLA genes associated with SSc are known to play a role in innate immunity, 
interferon signature and inflammation, adaptive immune responses, B- and 
T-cell proliferation, survival and cytokine production, apoptosis, autophagy, and 
fibrosis.
12. Neurological diseases
There is sufficient evidence to support the immunogenetic basis for some neu-
rological diseases, in particular, multiple sclerosis, Alzheimer’s disease, Parkinson’s 
disease, neuromyelitis optica, myasthenia gravis, and amyotrophic lateral sclerosis. 
Below provides a rapid overview of the immunogenetics of MS as the prototype of 
such neurological diseases.
12.1 Multiple sclerosis (MS)
It is the most common inflammatory disease of the CNS, which after inter-
fering with normal myelination results in axonal degeneration. The pathologic 
characteristics of MS are demyelinating lesions, which can be broadly classified 
according to whether or not autoimmune processes precede demyelination. 
In this manner, there are lesions arising from T-cell-mediated and T-cell plus 
antibody-mediated autoimmune encephalomyelitis, while sometimes demy-
elination is an initial clue resulted from viruses and toxins. Generally, MS is 
considered a chronic autoimmune disease, which is primarily characterized by 
activation of CD4+ autoreactive T cells and Th1 T-cell polarization and then by 
the production of antibodies, complement factors, and CD8+ T cells damaging 
the CNS tissues.
Studies suggest a strong genetic component for MS; more than 100 genetic loci 
have been so far identified to confer MS susceptibility. HLA genes totally account 
for about 10% of the genetic variance of MS. In particular, MHC class II gene HLA-
DRB1*1501 is present in about 50% of patients with MS. After that, the IL-7R-α 
chain gene can explain about 30% of all cases. Also, IL-2RA is another non-HLA 
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gene implicated in MS. Fresh evidence emerged that supports the potential of KIR 
genes as a risk or protective factor in the immunogenetics of MS. Both CD4+ T cells 
and NK cells express KIRs. CD4+ T cells that express KIRs are involved in antibody 
production and NK cells that express KIRs mediate antiviral and antitumoral innate 
immune responses. Therefore, KIR polymorphisms can affect the individual’s risk 
for MS through the impact they have on antiviral immunity and antibody produc-
tion. Now there is a big hope for the future of pharmacogenomics of MS when the 
immunogenetic information may help to predict treatment response, but it is not 
fulfilled yet!
13. Infectious diseases
13.1 Human immunodeficiency virus (HIV)
There is a variable degree of immunity to HIV. Genetic factors account for 
about one-fourth of this variation, among which are HLA genes that through 
interaction with CD8+ cytotoxic T and CD4+ helper T cells help the initia-
tion of anti-HIV adaptive immune responses, thereby conferring resistance to 
HIV. Studies have shown associations of HLA genes with accelerated disease 
progression, slow disease progression, protection against infection, reduced viral 
load levels, and increased susceptibility to infection. In addition, KIR genes have 
been implicated in resistance to HIV. More interesting is that the development of 
TB in people with HIV is, at least in part, determined by individual immunoge-
netic constitution.
13.2 Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Infection with HBV or HCV influences the expression of intrahepatic genes, 
thereby leaving patients liable to chronic liver disease, cirrhosis, and hepatocellular 
carcinoma. Virus-specific T-cell responses are central to the removal of infected 
hepatocytes, and therefore, the kinetics of these responses can aid in monitoring 
clinical recovery. In 1 year, about 2% of patients with chronic HBV infection will 
experience spontaneous viral clearance, which is characterized by HBV-specific 
T cells temporary appearing in the peripheral blood. Such an experience does not 
occur at all in the case of chronic HCV.
Genetic factors contribute to interindividual variation in clinical course of HBV 
and HCV infection. GWASs have identified HLA and non-HLA that confer suscep-
tibility to persistent HBV infection, progression of disease, and risk of HBV-related 
hepatocellular carcinoma. Again, both HLA and non-HLA genes have been linked 
with spontaneous clearance of HCV. Two genes MICA and DEPDC5 demonstrated 
association with HCV-related hepatocellular carcinoma.
13.3 Tuberculosis (TB)
Mycobacterium tuberculosis is recognized by innate immune receptors including 
TLRs, C-type lectin receptors (CLRs), and NLRs. Upon its recognition, different 
mechanisms by which immune cells (macrophages and T cells) and cytokines 
(IL-12, IFN-γ, IL-4, TNF-α, IL-10, IL-6, and TGF-β) can mediate antimycobacterial 
functions are engaged. Consistently, increasing evidence supports the individual 
genetic contribution to the control of tuberculosis infection, severe primary tuber-
culosis, and pulmonary tuberculosis. Genetic risk factors for developing TB include 
both HLA and non-HLA genes.
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14. Immunogenetics and immunosenescence
Immunosenescence refers to immune decline with age, which causes increased 
infection risk and related morbidity and mortality in the elderly. It is characterized 
by a chronic low-grade inflammation that arises from aberrant innate and adaptive 
immune responses, playing a role in a myriad of diseases including, but not limited 
to, atherosclerosis, obesity, type 2 diabetes, osteoporosis, osteoarthritis, neurode-
generative diseases, major depression, and malignancy. In the last four decades, 
immunosenescence has received great attention from geneticists. However, due 
to heterogeneous methodology, we are still unable to generalize the findings to all 
elderly people. In addition to HLA genes, non-HLA genes related to adaptive immu-
nity and to innate immunity appear to contribute to the immunogenetic network of 
human longevity.
15. Immunogenetics of atopic diseases
The most common chronic diseases afflicting children are asthma, hay fever 
(allergic rhinitis), and eczema (atopic dermatitis). Due to their strong associa-
tion with concurrent atopic dermatitis, both asthma and allergic rhinitis can 
be defined as a type of atopic diseases. In this manner, atopy can be used as an 
umbrella term that describes a group of diseases, e.g., asthma, allergic rhinitis, 
food allergy, and urticaria. Atopy is considered a result of a Th2-mediated pro-
cess, where Th2 cytokines promote the production of IgE by IgE+ memory B cells 
and plasma cells.
Genome screens show that, in general, atopic diseases are largely heritable 
(60%) and suggest that shared genes for atopy and other autoimmune diseases lie 
on the short arm of chromosome 6 where MHC gene are. In particular, the airway 
epithelium undergoes changes in asthma, and as a result, common genes are likely 
to cause asthma and other epithelial-based diseases, e.g., Crohn’s disease and pso-
riasis. In addition, genes encoding innate immune receptors and cytokines, which 
are central to the initiation and progression of allergic responses, contribute to the 
immunogenetic network of atopy.
16.  Vaccinomics and adversomics: immunogenetics and response to 
vaccination
Immune responses to vaccines vary between individuals. The main goal of 
vaccinomics is to deal with genes that may explain a substantial part of this varia-
tion. For example, studies estimate the variation in antibody response to hepatitis 
B surface antigen (HBsAg), measles virus, mumps virus, and rubella virus to be 
about 60, 88, 38, and 45% hereditary based. Generally, HLA and non-HLA genes 
encoding cytokines, cell surface receptors, and TLRs affect immune responses to 
vaccines, e.g., HBV, smallpox, MMR, and seasonal influenza. Moreover, there is 
evidence that genetic factors play a role in determining vaccine safety and adverse 
events, and consequently, it led to the emergence of adversomics. Overall, vac-
cinomics and adversomics facilitate prediction of vaccine efficacy and safety 
by using immunogenetic knowledge, and this in itself helps in developing more 
effective vaccines.
In this manner, immunogenetics aims to specify situations in which genetic muta-
tions cause the immune system to be functionally imperfect and secure solutions for 
them.
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